Novocure (NVCR) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Novocure Reports First Quarter 2017 Financial Results and Provides Company Update
April 27, 2017 6:00 AM EDTMore than 1,260 active patients at March 31, 2017, an increase of 59 percent from March 31, 2016, and 16 percent from December 31, 2016
First quarter 2017 net revenues of $34.9 million, reflecting 167 percent growth versus first quarter 2016 and 15 percent growth versus fourth quarter 2016
Final analyses of our EF-14 phase 3 pivotal clinical trial presented at AACR 2017 annual meeting demonstrate Optune plus temozolomide provides an unprecedented, landmark five-year survival advantage for newly diagnosed glioblastoma
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the three months ended March 31, 2017, highlighting year-over-year and sequential growth in... More
